4Leung N. Lamivudine for chronic hepatitis B. Expert Rev Anti Infect Ther,2004; 2:173-180.
5Lacombe K, Gozlan J, Boelle PY, et al. I.ong-term hepatitis B virus dynamics in HIV-hepatitis B virus-co infected patients treated with tenofovir disoproxil fumarate. AIDS, 2005.19:907-915.
6Squires K, Pozniak AL, Pierone G Jr, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med, 2003, 139(5Pt1):313-320.
7Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet, 2004, 43:595-612.
8Gallant JE, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis, 2003, 37: 944-950.
9van Bommel F, de Man RA, Stein K, et al. A multicenter analysis of antiviral response after one year of tenofovir mono therapy in HBV-monoinfected patients with prior nueleos(t)ide analog experience. J Hepatol, 2008,48: S32.
10Gane E, Benhamou Y, Gladysz A, et al. I.aek of influence of baseline genotype on antiviral response in subjects with chronic hepatitis b infection receiving tenofovir DF 300 mg QD for 1 year. A J Hepatol, 2008, 48:S256.
7Liver Failure and Artficial Liver Group,Chinese Society of Infectious Diseases,Chinese Medical Association.肝衰竭诊疗指南[J].实用肝脏病杂志,2006,9(6):321-324. 被引量：188
10DeChristoforo R. Tenofovir:a nucleotide analogue reverse transcriptase inhibitor for treatment of HIV infection[J].American Journal of Health-System Pharmacy,2004,(01):86-98.
